Obesity and Cancer: The Role of Dysfunctional Adipose Tissue

Overweight and obesity are health problems of epidemic proportions, increasing the risk not only of cardiovascular disease and type 2 diabetes mellitus but also of various types of cancer. Obesity is strongly associated with changes in the physiological function of adipose tissue, leading to insulin resistance, chronic inflammation, and altered secretion of adipokines. Several of these factors, such as insulin resistance, increased levels of leptin, plasminogen activator inhibitor-1, and endogenous sex steroids, decreased levels of adiponectin, and chronic inflammation, are involved in carcinogenesis and cancer progression. This article reviews these mechanisms, focusing on adipose tissue dysfunction as a unifying causal factor. Although understanding of the link between obesity and cancer might provide therapeutic targets, preventing overweight and obesity still remains number one priority. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2569–78)

[1]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[2]  C. Roehrborn,et al.  Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. , 2009, European urology.

[3]  D. English,et al.  Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition , 2009, Breast Cancer Research and Treatment.

[4]  Ross J. Harris,et al.  Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis , 2009, Cancer Causes & Control.

[5]  Thomas E Rohan,et al.  Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.

[6]  F. Visseren,et al.  Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. , 2008, European heart journal.

[7]  M. Jensen.  Role of body fat distribution and the metabolic complications of obesity. , 2008, The Journal of clinical endocrinology and metabolism.

[8]  M. Hoda,et al.  Mitogenic and anti‐apoptotic actions of adipocyte‐derived hormone leptin in prostate cancer cells , 2008, BJU international.

[9]  E. Motrescu,et al.  Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle , 2008, Biological chemistry.

[10]  T. Bjørge,et al.  Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. , 2008, American journal of epidemiology.

[11]  A. Russo,et al.  Insulin-dependent leptin expression in breast cancer cells. , 2008, Cancer research.

[12]  J. Chang-Claude,et al.  Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2008, Endocrine-related cancer.

[13]  M. Olszanecka-Glinianowicz,et al.  [Obesity as inflammatory disease]. , 2008, Postepy higieny i medycyny doswiadczalnej.

[14]  M. Czech,et al.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes , 2008, Nature Reviews Molecular Cell Biology.

[15]  J. Després,et al.  Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[17]  J. Manson,et al.  A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[18]  T. Sugimura,et al.  Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. , 2008, Carcinogenesis.

[19]  D. Hasenclever,et al.  Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. , 2008, Gynecologic oncology.

[20]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[21]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[22]  P. V. van Diest,et al.  Hypoxic regulation of metastasis via hypoxia-inducible factors. , 2008, Current molecular medicine.

[23]  A. Giordano,et al.  Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α , 2008, Oncogene.

[24]  A. Ray,et al.  Effects of adiponectin on breast cancer cell growth and signaling , 2008, British Journal of Cancer.

[25]  M. Woodward,et al.  Obesity and Risk of Colorectal Cancer: A Meta-analysis of 31 Studies with 70,000 Events , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  M. Gail,et al.  Cause-specific excess deaths associated with underweight, overweight, and obesity. , 2007, JAMA.

[27]  V. Beral,et al.  Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study , 2007, BMJ : British Medical Journal.

[28]  L. Beaulieu,et al.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  Alicja Wolk,et al.  Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. , 2007, The American journal of clinical nutrition.

[30]  S. Chua,et al.  Obesity, metabolic syndrome, and prostate cancer. , 2007, The American journal of clinical nutrition.

[31]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[32]  Bohan Wang,et al.  Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes , 2007, Pflügers Archiv - European Journal of Physiology.

[33]  M. Stumvoll,et al.  Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. , 2007, The Journal of clinical endocrinology and metabolism.

[34]  A. Russo,et al.  Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Larsson,et al.  Body mass index and pancreatic cancer risk: A meta‐analysis of prospective studies , 2007, International journal of cancer.

[36]  Philipp E. Scherer,et al.  Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans , 2007, Diabetes.

[37]  C. Mantzoros,et al.  Low adiponectin levels are associated with renal cell carcinoma: A case‐control study , 2007, International journal of cancer.

[38]  C. Vinson,et al.  The obesity-cancer link: lessons learned from a fatless mouse. , 2007, Cancer research.

[39]  C. Herder,et al.  Relationship between adipocyte size and adipokine expression and secretion. , 2007, The Journal of clinical endocrinology and metabolism.

[40]  K. Barrett,et al.  Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells , 2007, The British journal of surgery.

[41]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[42]  S. Katiyar,et al.  Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. , 2007, Free radical biology & medicine.

[43]  F. Visseren,et al.  The metabolic syndrome: metabolic changes with vascular consequences , 2007, European journal of clinical investigation.

[44]  M. Szymańska,et al.  Expression of Leptin, Leptin Receptor, and Hypoxia‐Inducible Factor 1α in Human Endometrial Cancer , 2007, Annals of the New York Academy of Sciences.

[45]  Graham A Colditz,et al.  Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.

[46]  D. Lawrence,et al.  Effect of pharmacologic plasminogen activator inhibitor‐1 inhibition on cell motility and tumor angiogenesis , 2006, Journal of thrombosis and haemostasis : JTH.

[47]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[48]  R. Hardy,et al.  The metabolic syndrome: A high-risk state for cancer? , 2006, The American journal of pathology.

[49]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.

[50]  F. S. Ambesi-Impiombato,et al.  Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. , 2006, European journal of cancer.

[51]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[52]  Simon G. Coetzee,et al.  Interleukin-6-Related Genotypes, Body Mass Index, and Risk of Multiple Myeloma and Plasmacytoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[53]  M. Hou,et al.  Serum adiponectin and leptin levels in Taiwanese breast cancer patients. , 2006, Cancer letters.

[54]  K. Lu,et al.  Association between adiponectin, insulin resistance, and endometrial cancer , 2006, Cancer.

[55]  H. Motoshima,et al.  Adiponectin Suppression of High-Glucose–Induced Reactive Oxygen Species in Vascular Endothelial Cells , 2006, Diabetes.

[56]  D. Berrigan,et al.  Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. , 2006, Cancer research.

[57]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[58]  J. Lagergren.  Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. , 2006, The Lancet. Oncology.

[59]  F. Révillion,et al.  Messenger RNA Expression of Leptin and Leptin Receptors and their Prognostic Value in 322 Human Primary Breast Cancers , 2006, Clinical Cancer Research.

[60]  A. Xu,et al.  Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. , 2006, Biochemical and biophysical research communications.

[61]  J. Olefsky,et al.  Inflamed fat: what starts the fire? , 2005, The Journal of clinical investigation.

[62]  T. Sørensen,et al.  Increased Risk of Intestinal Cancer in Crohn's Disease: A Meta-Analysis of Population-Based Cohort Studies , 2005, The American Journal of Gastroenterology.

[63]  W. Willett,et al.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. , 2005, Journal of the National Cancer Institute.

[64]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[65]  P. Sucharda,et al.  Angiogenic factors are elevated in overweight and obese individuals , 2005, International Journal of Obesity.

[66]  T. Asano,et al.  Adenosine Monophosphate-Activated Protein Kinase Suppresses Vascular Smooth Muscle Cell Proliferation Through the Inhibition of Cell Cycle Progression , 2005, Circulation research.

[67]  S. Kritchevsky,et al.  Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition Cohort , 2005, Cancer Epidemiology Biomarkers & Prevention.

[68]  L. Ellis,et al.  Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. , 2005, Cancer research.

[69]  Y. Kodera,et al.  Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer , 2005, British Journal of Cancer.

[70]  H. Yatsuya,et al.  Leptin Is Associated with an Increased Female Colorectal Cancer Risk: A Nested Case-Control Study in Japan , 2005, Oncology.

[71]  K. Ohba,et al.  Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. , 2005, The Journal of urology.

[72]  Jean-Daniel Zucker,et al.  Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. , 2005, Diabetes.

[73]  K. Çağlar,et al.  Prostate cancer and adiponectin. , 2005, Urology.

[74]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[75]  H. Münzberg,et al.  Molecular and anatomical determinants of central leptin resistance , 2005, Nature Neuroscience.

[76]  Jacob Seidell1.  Epidemiology of Obesity , 2005, Seminars in vascular medicine.

[77]  P. Carmeliet,et al.  Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth , 2004, Oncogene.

[78]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[79]  P. Stattin,et al.  Plasma Leptin and Breast Cancer Risk: A Prospective Study in Northern Sweden , 2004, Breast Cancer Research and Treatment.

[80]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[81]  P. Stattin,et al.  Obesity and colon cancer: Does leptin provide a link? , 2004, International journal of cancer.

[82]  C. Mantzoros,et al.  Adiponectin and breast cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[83]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. Ashkenazi,et al.  Tumor Necrosis Factor An Apoptosis JuNKie? , 2004, Cell.

[85]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[86]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[87]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[88]  P. Stattin,et al.  Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. , 2003, Oncology reports.

[89]  M. Lafontan,et al.  Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes , 2003, International Journal of Obesity.

[90]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[91]  T. Key,et al.  Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.

[92]  K. Hveem,et al.  Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. , 2003, JAMA.

[93]  D. Mcfadden,et al.  Differential effects of leptin on cancer in vitro. , 2003, The Journal of surgical research.

[94]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[95]  S. Feig.  IARC Handbooks of Cancer Prevention , 2003 .

[96]  E. Van Obberghen,et al.  Matrix Metalloproteinases Are Differentially Expressed in Adipose Tissue during Obesity and Modulate Adipocyte Differentiation* , 2003, The Journal of Biological Chemistry.

[97]  P. Garcia-Lorda,et al.  Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. , 2003, Obesity research.

[98]  J. Rakic,et al.  Role of plasminogen activator-plasmin system in tumor angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.

[99]  Hitoshi Nishizawa,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.

[100]  T. Key,et al.  Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women , 2003, Cancer Causes & Control.

[101]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[102]  D. Trichopoulos,et al.  Leptin and Body Mass Index in Relation to Endometrial Cancer Risk , 2002, Annals of Nutrition and Metabolism.

[103]  M. Kasuga,et al.  Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. , 2002, Diabetes.

[104]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[105]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[106]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[107]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[108]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[109]  D. Zakarya,et al.  Structure–cytotoxicity relationships for a series of HEPT derivatives , 2002, Journal of molecular modeling.

[110]  P. Morange,et al.  Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[111]  W. Ricart,et al.  No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance. , 2001, Obesity research.

[112]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[113]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[114]  E. Rimm,et al.  Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. , 2001, Atherosclerosis.

[115]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[116]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[117]  M. Waters,et al.  Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. , 2000, The Journal of clinical endocrinology and metabolism.

[118]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[119]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[120]  E Roman,et al.  High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[122]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[123]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[124]  Lark,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[125]  M. Marino,et al.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.

[126]  L H Kuller,et al.  Increased blood glucose and insulin, body size, and incident colorectal cancer. , 1999, Journal of the National Cancer Institute.

[127]  R. Busse,et al.  Leptin induces oxidative stress in human endothelial cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[128]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[129]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[130]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[131]  K. Heidenreich,et al.  Insulin Stimulates Mitogen-activated Protein Kinase by a Ras-independent Pathway in 3T3-L1 Adipocytes* , 1996, The Journal of Biological Chemistry.

[132]  R. Goyal,et al.  The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. , 1996, Gastroenterology.

[133]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[134]  X. Pi-Sunyer,et al.  The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. , 1994, The Journal of clinical endocrinology and metabolism.

[135]  L. Phillips,et al.  Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes. , 1993, Molecular endocrinology.

[136]  M. White,et al.  IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[137]  S. Coppack,et al.  Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. , 1992, Metabolism: clinical and experimental.

[138]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[139]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[140]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[141]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[142]  Aneta Cymbaluk,et al.  Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[143]  T. McKeever,et al.  A prospective study of weight change and systemic inflammation over 9 y. , 2008, The American journal of clinical nutrition.

[144]  John T. Woosley,et al.  Circulating levels of inflammatory cytokines and risk of colorectal adenomas. , 2008, Cancer research.

[145]  廣畑 富雄,et al.  Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective , 2007 .

[146]  D. Wasserman,et al.  Plasminogen activator inhibitor-1 modulates adipocyte differentiation. , 2006, American journal of physiology. Endocrinology and metabolism.

[147]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[148]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[149]  J. Arbiser,et al.  Reactive Oxygen-induced Carcinogenesis Causes Hypermethylation of p16Ink4a and Activation of MAP Kinase , 2002, Molecular medicine.

[150]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[151]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[152]  Who Consultation on Obesity.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.

[153]  H. Tongaonkar,et al.  Cancer prevention. , 1998, Indian journal of medical sciences.

[154]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .